Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Carboxypeptidase A4
(
CPA4
), a member of the metallo-carboxypeptidase family, is overexpressed in
liver cancer
and is associated with cancer progression. The role of
CPA4
in hepatocellular carcinoma (HCC) remains unclear. In this study, we aimed to evaluate the relevance of
CPA4
to the proliferation and expression of stem cell characteristics of hepatocellular carcinoma cells. Western blot analysis showed high
CPA4
expression in the
liver cancer
cell line Bel7402 and low expression in HepG2 cells. Knock-down of
CPA4
decreased cancer cell proliferation as detected by MTT and clone formation assays. The serum-free culture system revealed that downregulated
CPA4
suppressed the sphere formation capacities of tumour cells. However, upregulated
CPA4
increased the proliferation and sphere formation capacity. In addition, the protein expression of CD133, ALDH1 and CD44 also increased in cells with upregulated
CPA4
. In vivo, the overexpression of
CPA4
in tumour cells that were subcutaneously injected into nude mice markedly increased the growth of the tumours. These data suggest that
CPA4
expression leads to poor prognoses by regulating tumour proliferation and the expression of stem cell characteristics and may therefore serve as a potential therapeutic target of HCC.
...
PMID:Carboxypeptidase A4 promotes proliferation and stem cell characteristics of hepatocellular carcinoma. 3105 77
